article thumbnail

Lilly launches Mounjaro (tirzepatide), offers new treatment option for obesity and type 2 diabetes

Express Pharma

It is a treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. per cent and 2.1

Diabetes 101
article thumbnail

Ten tips for providing effective diabetes reviews

The Pharmacist

PCN pharmacy lead Gareth Malson offers his top ten tips for supporting people with diabetes to improve control of their condition at regular review The prevalence of diabetes is continuing to rise at an alarming rate. In 2023-24, the national diabetes register increased by around 21 people every hour, with 4.6m

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Megablockbusters are the holy grail. Here’s how drugmakers are getting there.

PharmaVoice

Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Development Library Events Press Releases PharmaVoice 100 Nominate 2024 PV100 2023 PV100 Sign up Search Sign up Search An article from Megablockbusters are the holy grail.

Diabetes 147
article thumbnail

IA-2A positivity could help develop effective intervention strategies in type 1 diabetes progression: GlobalData

Express Pharma

A recent study published in Springer Medizin has identified insulinoma-associated protein 2 autoantibody (IA-2A) positivity as a significant biomarker for disease progression in individuals at risk of type 1 diabetes (T1D). billion in 2023 to $9.9 billion in 2023 to $9.9 per cent, increasing from $2.2

article thumbnail

Tranq dope (fentanyl-xylazine combination): A new horizon in opioid withdrawal treatment

ALiEM - Pharm Pearls

Last Words Substance use disorders (SUD) are similar to other chronic relapsing medical conditions such as diabetes mellitus, congestive heart failure/cardiomyopathy, chronic obstructive pulmonary disorder, and cancer. 2023 Jan 1;53(1):140-2. 2022; 06/26/2023. 2023 Jun 1;36:89-91. 2023 Aug 1;89(2):231. 2023 [book].

article thumbnail

UCB reports success in phase 3 study of fenfluramine for CDD

Pharma Times

Content News Magazine Advertise Contact Competitions Connect Follow Follow Follow Follow Follow Legal Privacy Policy Terms and Conditions Editorial policy Cookies RSS – feed subscriptions © Copyright PharmaTimes Media Limited 2023

Diabetes 127
article thumbnail

AI-driven drug discovery, precision medicine, and sustainable manufacturing can redefine the pharma industry

Express Pharma

According to the Derwent World Patents Index from Clarivate, the number of pharma patents filed and granted by Indian companies has risen from 1,590 in 2013 to 8,793 in 2023, representing an increase from 0.5 per cent of global patents to almost 2 per cent.